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Background-—Dilated cardiomyopathy (DCM) is a leading cause of chronic morbidity and mortality in muscular dystrophy (MD)
patients. Current pharmacological treatments are not yet able to counteract chronic myocardial wastage, thus novel therapies are
being intensely explored. MicroRNAs have been implicated as ﬁne regulators of cardiomyopathic progression. Previously, miR-669a
downregulation has been linked to the severe DCM progression displayed by Sgcb-null dystrophic mice. However, the impact of
long-term overexpression of miR-669a on muscle structure and functionality of the dystrophic heart is yet unknown.
Methods and Results-—Here, we demonstrate that intraventricular delivery of adeno-associated viral (AAV) vectors induces
long-term (18 months) miR-669a overexpression and improves survival of Sgcb-null mice. Treated hearts display signiﬁcant
decrease in hypertrophic remodeling, ﬁbrosis, and cardiomyocyte apoptosis. Moreover, miR-669a treatment increases sarcomere
organization, reduces ventricular atrial natriuretic peptide (ANP) levels, and ameliorates gene/miRNA proﬁle of DCM markers.
Furthermore, long-term miR-669a overexpression signiﬁcantly reduces adverse remodeling and enhances systolic fractional
shortening of the left ventricle in treated dystrophic mice, without signiﬁcant detrimental consequences on skeletal muscle
wastage.
Conclusions-—Our ﬁndings provide the ﬁrst evidence of long-term beneﬁcial impact of AAV-mediated miRNA therapy in a
transgenic model of severe, chronic MD-associated DCM. ( J Am Heart Assoc. 2013;2:e000284 doi: 10.1161/JAHA.113.
000284)
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M uscular dystrophies (MDs) constitute a heterogeneousgroup of hereditary disorders, mainly characterized by
chronic muscle degeneration.1 MDs encompass, among
others, dystrophinopathies (eg, Duchenne MD [DMD]) and
sarcoglycanopathies (eg, recessive limb girdle MD [LGMD2])
forms. Dystrophin and sarcoglycans are components of the
dystrophin-associated glycoprotein complex (DGC).2 Genetic
disruption of DGC components leads to pathological calcium
leakage and chronic muscle ﬁber wastage.3 Beside skeletal
muscle impairment, chronic cardiomyopathy occurs in almost
all DMD patients who survive beyond their third decade,4 and
in 30% of LGMD2 patients.5 MD-associated cardiomyopathy
is characterized by arrhythmias, myocardial ischemia, cardio-
myocyte necrosis, and ﬁbrotic inﬁltrations. Affected myocar-
dium undergoes hypertrophic remodeling and ventricular
dilation, resulting in progressive functional deterioration
(dilated cardiomyopathy [DCM]).6
Currently, gene therapy is regarded as a promising tool for
reducing or counteracting cardiomyopathy progression in
MDs.7 However, gene therapy approaches must carefully
address the choice of animal models, vector types, and
expressed genes.8
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ORIGINAL RESEARCH
Animal models of MD-associated cardiomyopathy should
confront its complex and chronic manifestations. Mdx mice
genetically mimic DMD, but exhibit cardiomyopathic features
prevalently after 20 months of age.9 Conversely, Sgcb-null
mice, which genetically model LGMD2E sarcoglycanopathy,
already show necrotic foci in 9-week-old hearts and prominent
signs of ischemic-like lesions, arrhythmia, and DCM from
20 weeks of age.10 Notably, cardiomyopathy in Sgcb-null
mice features severe, chronic progression, and variable
worsening with age.
Because of its internal structure and well-protected position,
cardiac muscle therapy still poses challenges to vector delivery
and ﬁber transduction.11 Adeno-associated viral (AAV) vectors
appear to be a promising tool for efﬁcient gene delivery in
dystrophic hearts.12 Direct delivery of AAV-micro-dystrophin
into the cardiac cavity of newborn mdx mice resulted in
micro-dystrophin expression and DGC restoration in extensive
myocardial areas.13 AAV-mediated micro-dystrophin delivery
has been recently tested in the myocardium of 21-month-old
mdx mice, partially mitigating electrocardiogram (ECG) abnor-
malities, but not ﬁbrosis andmost hemodynamic parameters.14
Albeit promising in short term studies, the potential of
AAV-based therapies in chronic cardiac dysfunctions remains
largely unexplored in the long term.
Suitable candidates for heart gene therapy can be
identiﬁed in missing genes or cardiomyogenic factors, but
also noncoding RNAs, such as microRNAs (miRNAs).15
MicroRNAs are small, untranslated RNAs able to ﬁnely tune
expression or translational levels of downstream genes in a
wide range of processes, including cardiomyopathy and
dysfunctional heart remodeling.16 Cardiac-speciﬁc deletion
of Dicer, an essential endoribonuclease for miRNA processing,
led to DCM and heart failure.17 Altered levels of miR-1 and
miR-133a were implicated in cardiomyopathic and arrhythm-
ogenic processes,18,19 whereas miR-208a upregulation was
associated with adverse clinical outcome in DCM patients.20
Moreover, miR-669a downregulation has been recently shown
to couple calcium leakage and abnormal MyoD expression in
chronic DCM of Sgcb-null mice.21 However, assessment of
long-term effects of microRNA therapies in in vivo models of
chronic cardiomyopathy is still lacking.
In the present study, we investigated the long-term
(18 months) effects of AAV-mediated intraventricular
miR-669a delivery in Sgcb-null mice. Therapeutic relevance of
this approach was assessed by measuring histologic, molec-
ular, and functional properties of MD-associated end-stage
chronic cardiomyopathy. We show that miR669a expression is
maintained up to 18 months postinjection and results in
increased mice viability and marked reduction of adverse
hypertrophic remodeling and myocardial ﬁbrosis. Furthermore,
such miRNA therapy consistently alleviates cardiomyopathic
progression and increases left ventricular performance, as
evidenced by protein, gene and microRNA markers, and by
functional parameters. In addition, miR-669a delivery fails in
triggering off-target effects in the skeletal muscle of treated
mice. In summary, our study provides the ﬁrst evidence of
long-term, beneﬁcial effects of AAV-mediated in vivo miRNA
therapy of MD-associated advanced chronic cardiomyopathy.
Materials and Methods
Animal Procedures
All animal protocols were conducted in compliance with
Ethical Committee Guidelines of KU Leuven (project 095/
2012) and Belgian legislation. Sgcb-null mice were generated
by the group of K.P. Campbell10 (University of Iowa).
Recombinant AAV vectors were produced as previously
described.21 109 AAV2/9 particles in 10 lL PBS (sham,
10 lL PBS only) were delivered into pups (sham, n=15;
miR-dsRed, n=15; miR-669a, n=15; randomized groups)
through intraventricular puncture through the chest wall
within 24 hours after birth. Survival was monitored during
18 months. At 18 months postinjection, all surviving mice
(sham, n=3; miR-dsRed, n=3; miR-669a, n=7) were analyzed
using echocardiography and subsequently euthanized for
histologic and molecular analyses.
Histologic Analyses
Cardiac and skeletal muscle OCT-embedded transversal
cryosections were stained via Artisan Staining kit (Dako) for
Masson’s trichromic staining after ﬁxation in paraformalde-
hyde (4% paraformaldehyde [PFA] in PBS, 30 minutes at room
temperature) and Bouin’s solution (8 hours at room temper-
ature), according to manufacturer’s protocol. Sirius Red
staining was performed on formalin-embedded transverse,
5-lm-thick sections using Direct Red 80 reagent (Sigma) as
previously described,22 and pictures were taken with polarized
light and appropriate ﬁlter at Leica DM5500B microscope.
X-Gal staining was performed by overnight incubation at 37°C
of gluteraldehyde-ﬁxed cryosections with ready-to-use X-Gal
staining solution (Fermentas), followed by subsequent eosin
(Sigma) counterstaining. Terminal deoxynucleotidyl transfer-
ase dUTP nick end labeling (TUNEL) assay was performed on
cyosections, after ﬁxation ﬁrst in PFA, then in ethanol/acetic
acid, by Apoptag kit (Millipore), according to manufacturer’s
instructions. Bright ﬁeld and ﬂuorescence images were
acquired at 109 magniﬁcation via Eclipse Ti inverted micro-
scope (Nikon) and quantiﬁcations were conducted on >10
sections per mouse via ImageJ software. As regards trans-
mission electron microscopy, immersion ﬁxation was per-
formed by incubating the ventricle biopsies in PBS
supplemented with 4% PFA and 0.5% glutaraldehyde at 4°C
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for 4 hours. The samples were washed with PBS, carefully
minced, postﬁxed in 1% osmium tetraoxide in collidine buffer
for 1 hour at 4°C, then dehydrated through ice-cold gradient
EtOH series (25%, 50%, 75%, 80%, 90% and 100%) for
15 minutes each. Tissue samples were then routinely embed-
ded in Epon, ultrathin-sectioned (75 to 90 nm) and placed on
nickel grids. Grids were stained with a saturated solution of
uranyl acetate followed by Reynold’s lead citrate, then
examined by EM10 Zeiss Electron Microscope.
Immunostaining and Western Blot Analysis
Immunostaining reactions were performed on PFA-ﬁxed,
TritonX100-permeabilized (Sigma) transverse, 10-lm-thick
cryosections by overnight incubation at 4°C with primary
antibody in PBS supplemented with 5% w/v BSA (Sigma).
Primary antibodies and dilutions were as follows: chicken
antilaminin (Abcam), 1:300; mouse antisarcomeric a-actinin
(Abcam), 1:300; rabbit anti-Cx43 (SantaCruz), 1:300. All
secondary Alexa Fluor donkey antibodies (Life Technologies)
were diluted 1:500 in PBS supplemented with 5% w/v BSA.
Fluorescence images were acquired at 209 magniﬁcation via
Eclipse Ti inverted microscope (Nikon). Western blot (WB)
analysis was performed on 10 lg protein extracts on parallel
gels and primary antibody was incubated with nitrocellulose
blots overnight at 4°C in Tris-buffered saline (TBS) supple-
mented with 5% w/v skim milk powder (Sigma). Primary
antibodies and dilutions were as follows: rabbit anti-Cx43
(SantaCruz), 1:500; rabbit antiatrial natriuretic peptide (ANP)
(Millipore), 1:500. All secondary horseradish peroxidase (HRP)
-conjugated goat antibodies (SantaCruz) were diluted 1:5000
in TBS supplemented with 5% w/v skim milk powder. WB
imaging was performed on GelDoc chemiluminescence
detection system (BioRad) and protein levels were quantiﬁed
by relative densitometry, normalizing versus background and
Gapdh, through QuantityOne software (BioRad).
Gene/miRNA Expression Analyses
RNA was extracted from 10 mg cardiac tissue of all
surviving mice using RNA mini kit (Life Technologies). Reverse
transcription was performed using Superscript III kit (Life
Technologies) and gene expression was assessed via Sybr-
Green (Life Technologies) qPCR, after normalization versus
Pgk values. Primers; MyoD, Fw CCACTCCGGGACATAGACTTG-
ACA, Rev TCTGGTGAGTCGAAACACGGATCA; Agtr1a, Fw AG-
GAGCTGGATGGATTTGTGGGTT, Rev ACAAACAAGGTTCCTTGC-
CCTTGG; Il6, Fw TCCAGTTGCCTTCTTGGGACTGAT, Rev TAAG-
CCTCCGACTTGTGAAGTGGT; Il1b, Fw AGCAGCTATGGCAACT-
GTTCCTGA, Rev CAAAGGTTTGGAAGCAGCCCTTCA; Pgk, Fw
CAAAATGTCGCTTTCCAACAAG, Rev AACGTTGAAGTCCACCCT-
CATC. Total miRNA fraction was extracted from 10 mg
cardiac tissue of all surviving mice through miRNA isolation kit
(Life Technologies). Reverse transcription and Taqman-based
qPCR were conducted using miRNA-speciﬁc probes (Life
Technologies). Expression quantiﬁcation was normalized
versus miR-16 levels.
Functional Assessment
Mice were anesthetized using Isoﬂurane (1.5% to 2%,
Ecuphar). Subsequently, the animal was positioned in a
supine position on a heating pad and chest hair was removed
using a hair removing cream (Veet). Body temperature was
kept constant by feeding the signal of a rectal probe back to
the heating pad while heart and respiratory rates were
continuously monitored. Transthoracic echocardiography was
performed using a high frequency ultrasound system dedi-
cated to small animal imaging (VisualSonics Vevo 2100,
VisualSonics Inc) using a MS 400 linear array transducer (18
to 38 MHz). Parasternal short axis images at the level of the
papillary muscles were recorded as well as a parasternal long
axis image. All images were analyzed ofﬂine using dedicated
software (Vevo 2100 version 1.3, VisualSonics). Left ventricle
(LV) diameter at end-diastole (LVIDd) and end-systole (LVIDs),
and posterior wall thickness (PWT) were measured on the
short axis images as well as apex-to-base dimension of the LV
on the long axis image. From these measurements, fractional
shortening (FS) was calculated.
Skeletal Muscle Analyses
Transverse 7-lm-thick cryosections of soleus, tibialis anterior,
and diaphragm muscles, embedded in Tragacanth Gum, were
rehydrated with PBS and analysed for the presence of satellite
cells as previously described.23 Brieﬂy, after blocking, muscle
sections were stained with primary Pax7 (Hybridoma Bank,
Iowa University) and laminin (Sigma) antibodies and appro-
priate secondary antibodies (Molecular Probes) to identify
satellite cells under the basal lamina of muscle ﬁbers.
Sections were mounted on polylysine-coated slides with
ﬂuorescent mounting medium (DAKO) containing DAPI
(10 lg/mL). Fluorescence images were taken using a Zeiss
Axiophoto microscope (Carl Zeiss) and Metamorph image
capture software (Metamorph Production). Numbers of
satellite cells per muscle ﬁber in representative transverse
sections were counted and presented as percentages of
satellite cells.
Statistical Analysis
Survival curves were analyzed with Mantel-Cox and
Gehan-Breslow-Wilcoxon tests. Variation signiﬁcance was
scored when P<0.05 in both tests (*in ﬁgures and text). All
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data comparison analyses among sham, miR-dsRed ,and
miR-669a were analysed through Kruskal-Wallis test. When
Kruskal-Wallis test showed P<0.05 signiﬁcance among the
three groups, Mann-Whitney test was used to compare
miR-669a versus sham and miR-669a versus miR-dsRed.
Signiﬁcance was scored when P<0.05 in both analyses (**in
ﬁgures and text). All statistical tests mentioned above were
performed via Prism software (GraphPad).
Results
In Vivo miR-669a Therapy Ameliorates Survival
and is Maintained Long-Term
To determine long-term efﬁcacy and maintenance of in vivo
miR-669a therapy, AAV2/9 vectors bearing nuclear LacZ
cDNA (nLacZ) as tracer and, alternatively, two copies of
anti-dsRed miRNA (miR-dsRed) or miR-669a, as control
scramble and therapeutic miRNAs respectively, were gener-
ated and concentrated as reported (Figure S1,21). Newborn
Sgcb-null dystrophic mice were randomized into three groups
and injected with PBS (sham, n=15), AAV2/9-miR-dsRed
(miR-dsRed, n=15), or AAV2/9-miR-669a (miR-669a, n=15)
intraventricularly, and survival was monitored for 18 months.
Analysis of fatalities over time indicated that only miR-669a
treatment, but not miR-dsRed, did signiﬁcantly improve mice
survival, as compared to sham (Figure 1A).
In order to check for long-term maintenance of injected
vectors and expression of target miRNAs and tracers, the
myocardium of all mice surviving at 18 months postinjection
was analyzed for miR-669a and nLacZ expression. Quantitative
PCR (qPCR) data showed a signiﬁcant increase in miR-669a
levels only in miR-669a mice, as compared to sham and
miR-dsRed (Figure 1B). X-Gal histological staining revealed
virtually ubiquitous nLacZ expression throughout the myocar-
dium both in miR-dsRed and in miR-669a mice (Figure S2).
Thus, AAV-mediated miR669a therapy is maintained for at
least 18 months and miR-669a-treated, Sgcb-null mice show
signiﬁcant amelioration of survival rate over time, as
compared to controls.
miR-669a Expression Ameliorates Myocardial
Hypertrophy and Fibrosis
Hypertrophic remodeling and myocardial ﬁbrosis are hall-
marks of MD-associated DCM. In order to assess miRNA
therapy effects on ventricular hypertrophy, we analyzed
morphological pattern and cross-sectional area (CSA) values
of cardiomyocytes, as previously reported.24 Immunostaining
on myocardial sections revealed a heterogeneously unorga-
nized pattern of enlarged cardiomyocytes in sham and
miR-dsRed, whereas cardiomyocytes appeared smaller and
more compactly organized in miR-669a (Figure 1C). Accord-
ingly, quantitative analyses showed that treatment with
miR-669a signiﬁcantly decreased average cardiomyocyte
CSA (Figure S3) and dramatically shifted CSA value distribu-
tion toward lower classes (Figure 1D), as compared to sham
and miR-dsRed.
We next asked whether treatment with miR-669a induced
beneﬁcial effects on myocardial ﬁbrosis and cardiomyocyte
apoptosis. Fibrotic areas were revealed by histological staining
and quantiﬁed as percentage of total section area. Quantitative
analysis of intramyocardial ﬁbrotic areas using Masson’s
trichromic staining indicated a signiﬁcant reduction in
miR-669a mice, as compared to sham and miR-dsRed
(Figure 1E and Figure S4). Comparable results were quantiﬁ-
able after Sirius Red staining of collagen deposits (Figure S5).
Pyknotic nuclei quantiﬁcation by TUNEL assay, moreover,
revealed a signiﬁcant reduction in apoptotic nuclei in miR-669a
mice, as compared to sham and miR-dsRed (Figure S6).
Ventricular myocardium under chronic DCM conditions is
also characterized by impairment of sarcomeric structures25
and gap junctions,26 and by increased local release of ANP.27
Because of the beneﬁcial effects of miR-669 therapy on
hypertrophy, ﬁbrosis, and apoptosis, we sought to determine
whether miR-669a treatment triggered long-term effects also
on sarcomere organization, connexin-43 (Cx43) pattern, and
ANP levels. Transmission electron microscopy imaging
revealed disrupted and variably orientated myoﬁbrils in sham
and miR-dsRed myocardia, whereas sarcomere organization
was partially restored and de novo-forming myoﬁbrils were
visible after miR-669a treatment (Figure 1F). Immunostaining
revealed ameliorated Cx43 pattern at intercalated disks in
miR-669a mice, as compared to sham and miR-dsRed
(Figure 1G). Furthermore, protein analysis revealed that an
increase in Cx43 quantity and a decrease in ANP levels were
also signiﬁcantly quantiﬁable in the ventricular myocardium of
miR-669a mice, as compared to sham and miR-dsRed
(Figure 1H and Figure S7).
Hence, miR-669a therapy ameliorated hypertrophic remod-
eling, ﬁbrosis, and structural organization of end-stage
Sgcb-null myocardium.
miR-669a Expression Alters Cardiomyopathic
Gene/miRNA Signature
Given the long-term effects on survival and histological
properties, we then asked whether AAV-mediated miR-669a
therapy was also sufﬁcient to perturb transcription levels of
gene and miRNA markers of cardiomyopathy.
We examined myocardial levels of MyoD, abnormally
reactivated in Sgcb-null cardiac cells and a direct target of
miR-669a,21 and of Agtr1a, Il6 and Il1b, which were previously
shown to be upregulated in hypertrophic cardiomyopathy.28–30
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Quantitative PCR data indicated signiﬁcant downregulation
of all gene markers in miR-669a mice, as compared to sham
and miR-dsRed (Figure 2A).
Furthermore, we investigated potential alterations in
expression levels of miRNAs implicated in hypertrophy,
cardiac degeneration, and DCM. Beside miR-1, miR-133a,
and miR-208a, we quantiﬁed expression levels of miR-21,
miR-378, and miR-499, previously reported to be upregulated
during cardiomyopathy or cardiomyocyte stress.31–33 Quan-
titative PCR data showed signiﬁcant downregulation of miR-1
and miR-208a and upregulation of miR-133a in the myocar-
dium of miR-669a mice, as compared to sham and miR-dsRed
(Figure 2B). In addition, miR-21, miR-378, and miR-499 were
also signiﬁcantly downregulated (Figure 2B).
Figure 1. AAV-mediated miR-669a expression improves survival and cardiac tissue structure in Sgcb-null mice. A, Analysis of survival
percentages over time shows a signiﬁcant difference between miR-669a and control experimental groups (**P<0.05 according to Mantel-Cox and
Gehan-Breslow-Wilcoxon tests). B, qPCR data of miR-669a expression fold change as compared to sham. C, Immunostaining of Laminin (green,
nuclei counterstaining in blue) reveals hypertrophy-typical enlarged and unorganized cardiomyocytes in sham and miR-dsRed. Conversely,
miR-669a-treated myocardium shows a more regular pattern of smaller cardiomyocytes among experimental groups. D, Fiber percentage
distribution among cross-sectional area (CSA) classes reveals a shift of miR-669a-treated myocardium toward lower CSA values. E, Masson’s
trichromic staining reveals prominent ﬁbrotic scars or inﬁltrations (in blue) in sham and miR-dsRed, dramatically reduced in miR-669a condition. F,
Electron microscopy imaging shows sarcomere organization impairment (arrows) in sham and miR-dsRed, whereas sarcomeres partially recover
proper organization after miR-669a treatment (arrowheads). Inset, high magniﬁcation of a spiral polyribosome in close relationship with nascent
myoﬁbrils. G, Immunostaining of connexin-43 (green) and sarcomeric a-actinin (red) reveals improvement of Cx43-marked gap junctions in
miR-669a group, as compared to controls. H, Protein level quantiﬁcation of Cx43 and ANP indicates Cx43 upregulation and ANP downregulation in
miR-669a-treated myocardia (protein levels normalized vs miR-669a for dsRed, vs sham for Cx43 and ANP). Error bars depict standard deviation;
*P<0.05; **P<0.05 vs sham and P<0.05 vs miR-dsRed; scale bars, 100 lm (1 lm in F). Sham, n=3; miR-dsRed, n=3; miR-669a, n=7. AAV,
indicates adeno-associated viral; qPCR, quantitative polymerase chain reaction; Cx43, connexin-43; ANP, atrial natriuretic peptide.
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Thus, miR-669a sustained expression was sufﬁcient to
trigger long-term perturbation of many gene/miRNA markers
of cardiomyopathy.
Long-Term miR-669a Expression Alleviates
Cardiac Functional Impairment
DCMprogression affects not only histologic and contractile, but
also functional properties of the myocardium, resulting in
dilation of ventricular chambers,34 augmentation of posterior
wall thickness,35 and reduction of systolic fractional shorten-
ing.36 We therefore investigated whether miR-669a treatment
affected functional cardiac properties in all surviving mice at
18 months postinjection, using transthoracic echocardio-
graphy. Possible effects on DCM-related cardiac dysfunction
were measured by quantifying long axis of LV, posterior wall
thickness, ventricle diameter, and fractional shortening.
Treatment with miR669a, but not with miR-dsRed, signif-
icantly reduced the end-diastolic long axis dimension of the
LV (Lax-endo, Figure 3A). Moreover, posterior wall thickness
showed a signiﬁcant decrease in miR-669a mice, as compared
to sham and miR-dsRed (PWT, Figure 3A). Importantly,
long-term miR-669a expression signiﬁcantly decreased LV
internal diameter both in diastole and in systole (LVIDd and
LVIDs respectively, Figure 3B) and, as a consequence,
increased the systolic fractional shortening, as compared to
sham and miR-dsRed (Figure 3C).
Hence, echocardiography-based quantiﬁcations demon-
strated signiﬁcant alleviation of DCM dysfunctional phenotype
in miR-669a-treated mice at 18 months postinjection.
AAV-Mediated miRNA Therapy Does not Present
Off-Target Detrimental Effects in the Skeletal
Muscle
Because of the dramatic negative regulation exerted by
miR-669a on MyoD21 and the tropism of AAV serotype 2/9
also for skeletal muscle,37 we next sought to assess potential
long-term effects of AAV-mediated miRNA therapy on skeletal
muscle structure of injected dystrophic mice. In addition,
satellite cell (SC) number was also investigated, as an
indication of regenerative capability of the skeletal muscle.
Hind limb and diaphragm muscles of all surviving mice were
therefore analyzed for ﬁbrosis extension, ﬁber diameter, and
SC percentage per ﬁber.
X-Gal histological staining showed virtually absent nLacZ
expression in the skeletal muscles of sham, miR-dsRed, and
miR-669a mice (Figure S8A). Masson’s trichromic stain-
ing revealed deep ﬁbrotic inﬁltrations in gastrocnemius
muscles in all three experimental conditions, without
signiﬁcant differences (Figure S8B). Moreover, no signiﬁ-
cant differences were quantiﬁable in average CSA (Figure
S9) or CSA value distribution of gastrocnemius ﬁbers
among sham, miR-dsRed, and miR-669a conditions (Fig-
ure 4A). Similar results were also obtained by analyzing the
quadriceps muscles (data not shown). In addition, no
signiﬁcant differences were found when quantifying the
SC percentage/ﬁber in diaphragm, tibialis anterior, and
soleus muscles among the three experimental conditions
(Figure 4B).
Thus, AAV-mediated intraventricular delivery of both
miR-dsRed and miR-669a did not result in signiﬁcant delete-
rious effects on morphology and regenerative potential of hind
limb and diaphragm muscles of treated mice as compared to
sham conditions.
Figure 2. Effects of long-term miR-669a-based therapy on gene/
miRNA proﬁle of Sgcb-null hearts. A, qPCR data indicate signiﬁcant
decrease of MyoD, Agtr1a, Il6 and Il1b expression levels in
miR-669a-treated myocardium (fold change normalized vs sham). B,
Expression levels of miR-1, miR-208a, miR-21, miR-378 and miR-499
signiﬁcantly decrease, while miR-133a levels increase, in miR-669a--
treated myocardium (fold change normalized vs sham). Error bars
depict standard deviation; **P<0.05 vs sham and P<0.05 vs
miR-dsRed. Sham, n=3; miR-dsRed, n=3; miR-669a, n=7. miRNA
indicates MicroRNA; qPCR, quantitative polymerase chain reaction.
DOI: 10.1161/JAHA.113.000284 Journal of the American Heart Association 6
















MD-associated DCM is currently treatable only by symptom
alleviation, as effective cardioprotective or reparative inter-
vention is yet lacking. Taken together, our results provide the
ﬁrst evidence of long-term beneﬁcial effects of a miRNA
therapy in a murine model of MD-associated DCM. In fact,
AAV-mediated miR-669a expression is maintained for at least
18 months in Sgcb-null hearts, signiﬁcantly improves myo-
cardial structure and function, and reduces adverse left
ventricular remodeling, thereby increasing survival rate of
dystrophic, severely cardiomyopathic mice.
In our study, Sgcb-null dystrophicmice constituted a suitable
model to assess long-term effects and efﬁcacy of AAV-mediated
miRNA therapy. In fact, spontaneous, early onset, and severe,
chronic progression of DCM constitute a challenging yet
clinically relevant model to test novel therapeutic approaches.
Interestingly, miR-669a-mediated effects were consistently
quantiﬁable at 18 months postinjection, corresponding to an
end-stage point with regards to both life expectancy and
severity of cardiomyopathy in these mice.
In our approach, AAV2/9 vectors were tested. AAV vectors
are gathering increasing interest in the cardiac gene therapy
ﬁeld, given the susceptibility of cardiomyocytes to AAV
transduction.38 In addition, the 2/9 serotype recently showed
high tropism for the cardiac muscle also in nonhuman
primates.39 A possible drawback of AAV-based therapies
resides in variable immune response against viral capsids or
occasionally against AAV-transduced host cells.40,41 The main
limitation of the present study is that AAV particles were
injected before 24 hours after birth, escaping possible
immune responses by the developing host immune system.
In this regard, detailed studies are yet required to determine
immunological sustainability over time of such an AAV therapy
in juvenile or adult dystrophic mice.
Given the small size of miRNA molecules, many alternatives
to viral vectors are currently tested for cardiac miRNA delivery
or blockade, including injection of chemically modiﬁed
oligonucleotides.42 Oligonucleotide-based approaches could
bypass the obstacles posed by immune response and viral
genome integration, although durability and need of repeated
injections might still hamper applications on MD-associated
DCM cases.43 Our results indicate that a single AAV injection is
able to partially counteract cardiomyopathic progression for
up to 18 months in a small animal model of MD-associated
DCM.
In our experimental conditions, histological, protein, and
molecular assays showed signiﬁcant miR-669a-dependent
reduction of myocardial hypertrophy, apoptosis, and ﬁbrosis.
In accordance with previously reported data,21 miR-669a
overexpression was able to diminish aberrant MyoD levels in
the dystrophic myocardium also in the long term. MyoD
downregulation is likely linked to a decrease in aberrant
myogenic fate and in related apoptotic events during
Figure 3. Long-term miR-669a-based therapy alleviates MD-associated dilated cardiomyopathy. Echocardiography-based measurements show a
signiﬁcant improvement in distance between mitral valve and endocardial apex border (Lax-endo) and posterior wall thickness (PWT) (A) decrease
in left ventricle internal diameter both in diastole and in systole (LVIDd and LVIDs respectively, (B) and increase in the fractional shortening of the
left ventricle in miR-669a group, as compared to sham and miR-dsRed (C). Bars, average value; each data point refers to one mouse surviving at
18 months post-injection. **P<0.05 vs sham and P<0.05 vs miR-dsRed; sham, n=3; miR-dsRed, n=3; miR-669a, n=7. MD indicates muscular
dystrophy.
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remodeling of dystrophic myocardium, thus partially explain-
ing the beneﬁcial effects on treated hearts. Furthermore,
we observed potentially beneﬁcial variations also in
transcriptional levels of cardiac miRNAs that are involved in
cardiomyopathy and cardiac dysfunction. Notably, miR-669-
a-injected hearts displayed decreased miR-1 and miR-208a,
and increased miR-133a levels. Interestingly, miR-1 was
recently reported to suppress Cx43 in a model of myocardi-
tis.44 This could additionally explain Cx43 upregulation in
miR-669a-treated hearts. Furthermore, miR-208a downregula-
tion correlates with decreased remodeling, as miR-208a-null
mice fail to undergo hypertrophy and ﬁbrosis in response to
several forms of cardiac stress.45 Conversely, miR-133a
upregulation can counteract Caspase9-mediated apoptosis
upon myocardial injury.46 Moreover, miR-133a downregulation
has been recently shown to further worsen prohypertrophic
calcium signaling and pathological remodeling in the heart.47
However, changes in global miRNA levels could theoretically
lead to adverse side events (eg, high miR-133a levels have
been associated with retinal degeneration).48 Although far
from the scope of this work, a systemic investigation in
off-target organs is in fact required to address possible
detrimental effects of such miRNA therapies.
Importantly, intraventricular miR-669a delivery ameliorated
structure and function of DCM hearts, apparently without
inducing off-target detrimental effects in the skeletal muscle.
Moreover, after miR-669a treatment, neither the dystrophic
muscle wastage, nor the SC percentage was different from
control groups. Interestingly, nuclei positive to nlacZ staining
were virtually absent in skeletal muscles of AAV-injected
mice. Given MyoD-dependent effects on the delicate balance
between quiescence and apoptosis in SCs,49 it might
be possible that rare miR669a-transduced SCs were
eventually withdrawn from the muscles after repeated cycles
of de/regeneration, typical of MD progression.
In summary, this study provides the ﬁrst evidence of
long-term (18 months) beneﬁcial effects of AAV-mediated
miR-669a therapy in a murine model of MD-associated
chronic DCM. Further reﬁnement of administration routes
and combination with cell therapy will potentially increase
therapeutic effectiveness of miRNA-based strategies for MD
cardiomyopathy.
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